Healthcare Dec 27, 2021 08:56 PM (GMT+8) · EqualOcean
On the evening of February 27, Kaifa pharmaceutical Hong Kong stock issued an announcement announcing the progress of phase III clinical trial of prochloramide in the treatment of mild and moderate non hospitalized new crown patients. The announcement shows that according to the interim analysis data of 348 patients with new crowns, the number of events is less and does not reach statistical significance. The company plans to adjust the clinical trial plan and seek the consent of regulatory agencies such as FDA to continue to recruit high-risk new crown patients with only basic diseases and / or no history of new crown vaccination. Based on the interim analysis results, the safety of prochloramide was good, and no drug-related serious adverse events were reported.